Appointment of a new Director to the Board of Directors of Immune Biosolutions Inc.

We are thrilled to welcome a new director to the board of directors of Immune Biosolutions Inc: Mr. Nicholas Franco. The arrival of Mr. Franco is part of the company’s development strategy. With over 32 years of experience in the pharmaceutical industry, research, marketing, sales, and business development in several therapeutic areas, both domestically and internationally, “He will certainly bring a unique strategic perspective of the industry and a vision focused on value creation to the Board,” says Luc Paquet, CEO of the company.

NewsGuest UserMay 1, 2023BIOOQuébecImmune Biosolutions, Board of directors

Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron

Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug candidate maintains a potent activity in neutralization assays. Recent results have confirmed that this drug, IBIO123, is capable of neutralizing SARS-CoV-2 (COVID-19) and all its current variants of concern (VOCs) that have emerged throughout the pandemic, including the latest Omicron variant. IBIO123 is an inhaled antibody-based immunotherapy with an ongoing multisite phase 1 and 2 clinical program for the treatment of symptomatic SARS-CoV-2 patients.

NewsCatherine LamontagneJanuary 11, 2022Immune Biosolutions, COVID-19, Omicron

Appointment of Luc Paquet as Chief Executive Officer - Immune Biosolutions enters into a new chapter of its growth

Immune Biosolutions Inc. is consolidating its biopharmaceutical transition, following the accelerated development of its activities. The company will focus its activities towards the discovery and development of immunotherapies for infectious diseases, inflammation and cancer. To propel Immune Biosolutions' growth in this new phase, the company is pleased to announce the appointment of Mr. Luc Paquet as Chief Executive Officer.

NewsCatherine LamontagneNovember 11, 2021Immune Biosolutions

Immune Biosolutions Receives C$13.44 Million to Develop and Biomanufacture its Promising Immunotherapy to Treat COVID-19 and its Variants

SHERBROOKE, Québec (March 16, 2021)—Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada’s Strategic Innovation Fund (SIF) to develop its promising immunotherapy whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants.

NewsGuest UserMarch 16, 2021Investments, COVID-19, Immune Biosolutions, Immunotherapy

Immune Biosolutions, DIEX Recherche, Université de Sherbrooke and Keyrus Life Science Partner up to Fight COVID-19

Immune Biosolutions, Diex Research, Keyrus Life Science and the Faculty of Medicine and Health Sciences of the Université de Sherbrooke (FMSS) are joining forces to discover and develop innovative solutions against the SARS-CoV-2 virus.

NewsGuest UserApril 21, 2020COVID19, Immune Biosolutions, DIEX Recherche, Keyrus Life Sciences, UdeS, partnership

New Board of Directors Appointments for Immune Biosolutions

Immune Biosolutions, an early-stage biopharmaceutical company focusing on the discovery, engineering and development of therapeutic humanized chicken antibodies, today announced the appointments of Drs. Nadine Beauger and Louise Proulx to its Board of Directors.

NewsGuest UserJanuary 22, 2020chicken antibodies, Board of directors, Immune Biosolutions